ALX Oncology Holdings Inc (NASDAQ:ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive gastric/gastroesophageal junction cancer.
Cyramza (ramucirumab) is owned by Eli Lilly And Co (NYSE:LLY).
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased